ClinicalTrials.gg
CompletedNCT03741283OptiNAMUpdated Nov 13, 2026

Optimisation of Nutrition and Medication for Acutely Admitted Older Medical Patients

An interventional study of Optimisation of nutrition and medication in Aging, Malnutrition and Drug Prescribing, sponsored by Hvidovre University Hospital. Completed at 1 site in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Hvidovre University Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
193
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 42 studies in Malnutrition with a site in Denmark — 8 open to participants now, 10 under way, none of them phase 3. Malnutrition · Denmark.

Enrollment
8th of 35
193 · median 48
Started
2018
with 3 others
No phase
32 of 42
6 open now
Registered
22nd of 42
by date
Lead sponsor
4 of 42
Hvidovre University Hospital

Among the 42 studies in Malnutrition with a site in Denmark, this one is the 8th largest by enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2018, is one of 32 with no phase, and was the 22nd registered.

Malnutrition

1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.

Browse Malnutrition studies →

Open to participants now

8 of the 42 studies in Malnutrition with a site in Denmark are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Malnutrition with a site in Denmark, or all of them as a file.
02

Study summary

Malnutrition and inappropriate medication prescribing are highly prevalent among acutely admitted older medical patients leading to re-admissions, frailty, poor physical, performance compromised quality of life and mortality. Thus, the aim of this study is to optimise the nutrition and medication in older medical patients admitted to an acute care department at admission and up to 16 weeks after discharge. Participants in the intervention group receives a medication review and participants with malnutrition or risk of malnutrition additionally receive a transitional multimodal intervention. The control group receives standard care.

Read the detailed description

The OptiNAM study is designed as a single-blinded randomised controlled trial starting upon admission and continues till 16 weeks after discharge. The trial has five sub-studies with three independent primary endpoints, all with individual sample size calculations.

The study consists of an intervention group and a control group. The control group receives standard care.

Patients that meet all inclusion criteria and none of the exclusion criteria are invited to participate. After signing a written informed consent, the participants are block randomised to either the intervention or control group.

The intervention group receives a personalised rehabilitation program, which is described below. Outcome measures are performed at baseline, week 8 and week 16 after after discharge, cf. section regarding outcome measures.

Sub study 1, Malnutrition:

As malnutrition among older patients has multifactorial etiology sub-study 1 investigates the effects of a multimodal transitional intervention on quality of life in acutely admitted older patients with malnutrition or risk of malnutrition (according to the Mini Nutritional Assessment - Short Form) from baseline (admission day) and 16 weeks after discharge compared to standard care. The intervention includes a medication review (cf. sub-study 2), a dietetic intervention and if clinical relevant physiotherapeutic-, occupational-, geriatric- and/or odontological intervention. It is secondary hypothesised that a multimodal intervention compared to standard care may improve the quality of life, nutritional status, energy- and protein intake, symptoms which compromise nutritional intake, physical performance, cognitive function, frailty, re-admissions, inflammation and biomarkers. A cost-benefit analysis will be conducted.

Dietetic intervention: The study subjects receives a personal diet plan during admission. The diet plan is reviewed at discharge by a dietician. To ensure optimal energy- and protein intake after discharge, a community-based dietician visit the participants for one hour in week 1, 2, 4 and 8.

Physiotherapeutic intervention: Participants with low ability to perform groceries shopping, cooking and/or eating are offered a community-based strength, balance and endurance training after discharge if they also have low muscle strength in the lower extremities. The training sessions are based on algorithms, have a duration of one hour, and are offered twice a week for 16 weeks after discharge.

Occupational intervention, Dysphagia: If relevant (EAT-10 score >=3), a hospital-based occupational therapist review and treat the dysphagia based on the Facial Oral Tract Therapy (FOTT) principle during admission. During the first week after discharge a community-based occupational therapist continues with the treatment. A maximum of two weekly visits of one hour throughout the interventions period is offered.

Occupational Intervention, low Ability to perform Activities of Daily Living (ADL): If the participant has low ability to perform grocery shopping, cooking and eating (evaluated by Functional Recovery Score \<=2) then a community-based occupational therapist visit the participant during the first two weeks after discharge to evaluate the quality of activities of daily living. If relevant, and if there is a rehabilitation potential, seven visits of one hour is offered during the 16 weeks after discharge.

Geriatric intervention: If relevant (a Mini Geriatric Depression Score >=2), a geriatric physician conducts a clinical assessment of depression during admission and initiate treatment if necessary.

Odontological intervention: If relevant (participant reported pain in mouth, difficulties chewing or xerostomia), a dentist evaluate the dental status and oral health during admission, and if necessary encourage the participant to consult a dentist after discharge. If a participant shows insufficient oral hygiene a dental hygienist visits the participant after discharge twice during after discharge.

Sub-study 2, Medication optimisation:

Medication prescription for older patients is challenging and may be attributed to marked inter-individual variations in general health, comorbidities, organ function, pharmacokinetic and pharmacodynamic properties, biological age and physical performance. Thus, the "one size fits all" approach is probably inappropriate in older patients. The aim of sub-study 2 is to investigate the investigate the effect of an inter-professional conducted medication review during admission in an acute care department regardless of the nutritional status in the study participant, thus all subjects in the intervention group receive a medication review. It is hypothesized that inter-professional conducted medication reviews reduce the Medication Appropriateness Index score (MAI score) in the intervention group eight weeks after discharge compared to the control group. It is secondary hypothesized that inter-professional conducted medication reviews improve: lack of medication prescribing for a condition/disease, inappropriate polypharmacy and suboptimal medication prescribing of high risk medications.

Sub-study 3, Accuracy of renal function estimates and the consequence for prescribing recommendations guidelines:

Accuracy in renal function estimates is essential for optimization of medication prescribing since 40 % of all medication or their active metabolites is renally excreted. Lack of medication prescribing and dose adjustment according to the renal function is common in older patients with renal impairment and can result in overdosing, adverse drug reactions, hospital admissions, reduced quality of life and mortality. The gold standard for measuring glomerular filtration rate (GFR) is an exogenous filtration marker. However, this method is costly, time consuming and thus impractical in a clinical setting. Therefore, GFR is often estimated on serum concentrations of an endogen biomarker. Sub-study 3 aim to investigate which biomarker(s) and equation most accurately estimate the GFR in older medical patients who have been acutely admitted.

Sub-study 4, Pharmacogenetic test on cytochrome 450 variations and its potential for optimization of medication prescribing:

Cytochrome 450 enzymes are responsible for metabolism of up to 80% of all medications. The enzyme complex is mainly found in liver but are also present in intestinal mucosa, skin, lungs, brain and kidneys. There are major genetic inter-individual differences in the activity of the CYP 450 complex, resulting in lack of therapeutic effects, lack of effect or adverse drug reactions. Insight into these genetic inter-individual differences via pharmacogenetic tests possess a potential in optimization of medication prescribing with regard to therapeutic effects, compliance and risk of side effects. Thus, sub-study 4 wish to descriptively investigate the potential of pharmacogenetic test on cytochrome 450 variations.

Sub-study 5, Assessment of Frailty:

Frailty is a common clinical syndrome in older adults and defined as state of increased vulnerability resulting from decline in reserve capacity and function across multiple physiologic systems. Frailty affects the person's ability to cope with everyday life and leads to high risk for falls, disability, hospitalization and mortality. The frailty assessment is based on two different frailty scoring systems, Frieds "Frailty Phenotype" and Morley's "Frail Scale", examined at admission and 8 and 16 weeks after discharge. The purpose of the assessment is to evaluate which frailty measure is the best applicable in describing the patients and changes in their functional level. As there is no gold standard we use FI-Outref as an independent measure of frailty. FI-OutRef is a Frailty Index, based on standard admission laboratory test results Outside of the Reference interval.

03

Conditions studied

  • Aging
  • Malnutrition
  • Drug Prescribing

Keywords

  • Medicines optimisation
  • Multimodal interventions
  • Inflammation
  • Emergency Service, Hospital
  • Pharmacogenetics
  • Renal function
  • Food intake
  • Quality of life
  • Polypharmacy
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥65 years
  • Acutely admitted medical patients
  • Understand and speak Danish
  • Caucasian
  • Resident in Municipality: Brøndby, Hvidovre or Copenhagen

Exclusion criteria

Exclusion Criteria:

  • Unable to cooperate cognitively
  • Terminal/suicidal patients
  • Patients in isolation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
193 participants (actual)

Study arms

  • Experimental
    Optimisation of nutrition and medication

    N=approx. 65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition.

    Other: Optimisation of nutrition and medication

  • No intervention
    Standard care

    N= approx. 65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition.

Interventions

  • OtherOptimisation of nutrition and medication

    1. Inter-professional optimisation of medication prescribing: Study participants in the intervention group receives optimisation of medication prescribing at admission day (baseline) regardless of nutritional state. The intervention is performed in cooperation between a clinical pharmacist and a medical physician. 2. Nutritional intervention: If positive screening for malnutrition or risk of malnutrition a dietetic intervention is initiated and if positive screening below interventions are initiated: * Dysphagia: occupational therapy intervention. * Oral cavity problems: odontological intervention. * Depression: geriatric intervention. * Low ADL: occupational therapy intervention and if positive screening for poor muscle strength: physiotherapeutic intervention.

06

What researchers measure

Primary outcomes

  1. Changes in quality of life score EuroQol- 5 Dimensions- 5 Levels (sub-study 1)

    Patient administered quality of life scoring system with focus on mobility, daily activities, pain and discomfort and depression.

    Time frame: Baseline (admission day), week 8 and week 16.

  2. Changes in Medication Appropriateness Index-score" (sub-study 2)

    Medical physician, geriatric or senior pharmacist perform the MAI-scoring to evaluate the appropriateness of the medication prescribing.

    Time frame: Baseline (admission day), week 8 and week 16.

  3. Accuracy of renal function estimates (sub-study 3) - cystatin C

    Differences between GFR measured by a renally excreted radioactive labeled isotope (chromium 51-Cr-EDTA or 99mTc diethylenetriaminepentaacetic acid) and estimated GFR based on Creatinine and Cystatin C or a combination of the biomarkers.

    Time frame: Baseline (admission day) or no later than 14 days after admission

Secondary outcomes

  1. Walking speed to evaluate the development in physical performance

    4-Meter Walk Test

    Time frame: Baseline (admission day), week 8 and week 16.

  2. Functional measurement to evaluate the development in physical performance

    30-second chair stand test

    Time frame: Baseline (admission day), week 8 and week 16.

  3. Functional measurement to evaluate the development in physical performance

    handgrip strength test

    Time frame: Baseline (admission day), week 8 and week 16.

  4. Functional measurement to evaluate the development in physical performance

    The de morton mobility index

    Time frame: Baseline (admission day), week 8 and week 16.

  5. Measure of physically active time and number of steps taken

    Assessed by applying an activPAL chip to the thigh for one week

    Time frame: Week 1, week 8 and week 16 after discharge

  6. Frailty assessment

    Fried frailty phenotype

    Time frame: Baseline (admission day), week 8 and week 16.

  7. Frailty assessment

    Morleys frail questionnaire

    Time frame: Baseline (admission day), week 8 and week 16.

  8. Anthropometric measurement to monitor changes in bodyweight

    Bodyweight

    Time frame: Baseline (admission day), week 8 and week 16.

  9. Cognitive test aiming to evaluate cognitive function

    Orientation Memory Concentration test

    Time frame: Baseline (admission day), week 8 and week 16

  10. Patient records

    Contacts related to the health care system, medication lists, use of municipal services

    Time frame: Baseline (admission day), week 8 and week 16.

  11. Standard admission blood work

    ALAT, albumin, alkaline phosphatase, bilirubin, CO2, CRP, haemoglobin, INR, K+, blood urea nitrogen, coagulation factors, leucocytes, neutrophils, MCH, MCV, Na+, thrombocytes, lactate-dehydrogenases, NGAL, β-trace protein and β-trace microglobulins.

    Time frame: Baseline (admission day), week 8 and week 16.

  12. Quality of life score, WHO-5

    Patient administered quality of life scoring system with focus on general well-being on a scale from 0-100.

    Time frame: Baseline (admission day), week 8 and week 16

  13. Cognitive performance

    Mini mental state examination

    Time frame: Week 8 and week 16

  14. Cognitive performance

    Hopkins verbal learning test

    Time frame: Week 8 and week 16

  15. Cognitive performance

    Trail making test

    Time frame: Week 8 and week 16

  16. Cognitive performance

    Digit Symbol Substitution test

    Time frame: Week 8 and week 16

  17. Assessment of dietary intake after admission

    24 hours dietary recall

    Time frame: Week 8 and week 16

  18. Evaluation of medication under-prescribing

    Assessment of underutilization Index (AOU)

    Time frame: Baseline (admission day), week 8 and week 16

  19. Inflammatory marker to evaluate the inflammatory state

    SuPAR

    Time frame: Baseline (admission day), week 8 and week 16.

  20. Polypharmacy

    The number of patients in polypharmacy

    Time frame: Baseline (admission day), week 8 and week 16.

  21. Potentially inappropriate medication to elderly

    The number of potentially inappropriate medication prescriptions

    Time frame: Baseline (admission day), week 8 and week 16.

  22. Acceptance of suggested changes in medications

    Frequency of physicians' acceptance of suggested changes in medications

    Time frame: Baseline (admission day), week 8 and week 16.

  23. Accuracy of renal function estimates - all biomarkers

    Differences between GFR measured by a renally excreted radioactive labeled isotope (chromium 51-Cr-EDTA or 99mTc diethylenetriaminepentaacetic acid) and estimated GFR based on Creatinine, Cystatin C, Beta-trace protein, Beta-2 microglobulin or a combination of the biomarkers.

    Time frame: Baseline (admission day) or no later than 14 days after admission.

  24. Dosing discrepancies of renal risk medication

    Frequency of renal risk medication prescribed in disagreement to clinical recommendation guidelines based on measured GFR and the choice of eGFR biomarker.

    Time frame: Baseline (admission day) or no later than 14 days after admission.

  25. Nutritional status

    Screening scores for undernutrition with Mini Nutritional Assesment - Short Form, Eating validation scheme, Nutritional Risk Screening-2000

    Time frame: Baseline (admission day), week 8 and week 16.

  26. Intestinal microbiome composition

    Composition and changes in the intestinal microbiome.

    Time frame: Baseline (admission day), week 8 and week 16 after discharge.

  27. Body composition

    Description and changes in body composition, assessed by bioelectric impedance analysis (InBodyS10).

    Time frame: Baseline (admission day), daily through out admission, up to three weeks after admission during kidney function measurement, week 8 and week 16 after discharge.

  28. Body composition

    Assessed by dual x-ray absorptiometry (DXA)

    Time frame: Up to three weeks after admission during kidney function measurement

Other outcomes

  1. Number and types of actionable gene variants - Pharmacogenetic test

    The number of actionable gene variants identified by the pharmacogenetic test

    Time frame: Baseline (admission day)

  2. Number and types of recommended therapy changes -Pharmacogenetic test

    The number of actionable gene variants identified by the pharmacogenetic test

    Time frame: Baseline (admission day)

  3. Health economy related to Sub-study 1

    Health care costs will be evaluated in regards to changes in quality of life measured by EURO-Qol-5D-5L.

    Time frame: Baseline (admission day), week 8 and week 16 and 1 year after discharge

07

Study locations

1 site
  • Amager & Hvidovre Hospital
    Hvidovre, Capital Region 2650, Denmark
08

References and documents

Publications

  • Andersen AL, Houlind MB, Nielsen RL, Jorgensen LM, Bengaard AK, Bornaes O, Juul-Larsen HG, Hansen NM, Brochner LD, Hansen RG, Skovlund CAR, Pedersen AML, Beck AM, Pedersen MM, Petersen J, Andersen O. Effectiveness of a multidisciplinary and transitional nutritional intervention compared with standard care on health-related quality of life among acutely admitted medical patients aged >/=65 years with malnutrition or risk of malnutrition: A randomized controlled trial. Clin Nutr ESPEN. 2024 Jun;61:52-62. doi: 10.1016/j.clnesp.2024.02.031. Epub 2024 Mar 13. PubMed 38777473 ↗
  • Iversen E, Bengaard AK, Leegaard Andersen A, Tavenier J, Nielsen RL, Juul-Larsen HG, Jorgensen LM, Bornaes O, Jawad BN, Aharaz A, Walls AB, Kallemose T, Dalhoff K, Nehlin JO, Hornum M, Feldt-Rasmussen B, Damgaard M, Andersen O, Houlind MB. Performance of Panel-Estimated GFR Among Hospitalized Older Adults. Am J Kidney Dis. 2023 Dec;82(6):715-724. doi: 10.1053/j.ajkd.2023.05.004. Epub 2023 Jul 28. PubMed 37516299 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Aug 2022, 46 months.

Of 393 non-industry interventional studies with no phase under Malnutrition, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 46 months is above that.

Counting every sponsor, half of 419 studies reached it within 22 months; a quarter within 11 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Jul 2022 → Aug 2022 and completion Jul 2022 → Aug 2022.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2018
First posted
Nov 14, 2018
StartActual
Oct 15, 2018
Primary completionActual
Aug 30, 2022was Jul 2022
CompletionActual
Aug 30, 2022was Jul 2022
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 13, 2026
Sites
1 site added, 1 site removed
Show site
  • Amager & Hvidovre Hospital · Hvidovre, Denmark
Show 1 removed
  • Amager & Hvidovre Hospital · Hvidovre, Denmark
Nov 13, 2026
Primary completion
Jul 15, 2022→Aug 30, 2022 (actual)
Nov 13, 2026
Study completion
Jul 15, 2022→Aug 30, 2022 (actual)
Nov 13, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 38777473 ↗
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Status unknown→Completed
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 38777473 ↗
    1 site added, 1 site removed
    Show site
    • Amager & Hvidovre Hospital · Hvidovre, Denmark
    Show 1 removed
    • Amager & Hvidovre Hospital · Hvidovre, Denmark
    Primary completion Jul 15, 2022→Aug 30, 2022 (now actual)
    Study completion Jul 15, 2022→Aug 30, 2022 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03741283
Collaborators
Clinical Research Centre, Region Hovedstadens Apotek, Udviklings- og forskningspuljen, Danske Regioner og Sundhedskartellet, Region Capital Denmark, Regionernes Lægemiddelorganisation
Responsible party
Ove Andersen (Head of Clinical Research Centre, Hvidovre University Hospital) — Principal investigator
First posted
Nov 14, 2018
Start date
Oct 15, 2018
Primary completion
Aug 30, 2022
Completion
Aug 30, 2022
Last update
Nov 13, 2026

Study contacts

Ove Andersen, MD, PhD
study chair · Hvidovre University Hospital
Aino L. Andersen, MSc
principal investigator · Hvidovre University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion